250
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Efficacy of a Single Intra-Articular HYMOVIS ONE Injection for Managing Symptomatic Hip Osteoarthritis: A 12-Month Follow-Up Retrospective Analysis of the ANTIAGE Register Data

, , ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 19-26 | Published online: 04 Mar 2020

References

  • Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010;26(3):355–369. doi:10.1016/j.cger.2010.03.00120699159
  • Roman-Blas JA, Bizzi E, Largo R, Migliore A, Herrero-Beaumont G. An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease. Expert Opin Pharmacother. 2016;17(13):1745–1756. doi:10.1080/14656566.2016.120107027326466
  • Nemes S, Gordon M, Rogmark C, Rolfson O. Projections of total hip replacement in Sweden from 2013 to 2030. Acta Orthop. 2014;85(3):238–243. doi:10.3109/17453674.2014.91322424758323
  • Kurtz SM, Ong KL, Lau E, Bozic KJ. Impact of the economic downturn on total joint replacement demand in the United States: updated projections to 2021. J Bone Joint Surg Am. 2014;96(8):624–630. doi:10.2106/JBJS.M.0028524740658
  • Bagge E, Bjelle A, Valkenburg HA, Svanborg A. Prevalence of radiographic osteoarthritis in two elderly European populations. Rheumatol Int. 1992;12(1):33–38. doi:10.1007/BF002468741598499
  • Sperati A, Picconi O, Tancioni V, Guasticchi G, Agabiti N. Outcomes of hip replacement: a hospital-based longitudinal study in Lazio region (Italy). Ann Ig. 2008;20(2):141–157.18590046
  • Zhang W, Doherty M, Arden N, et al.; EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). EULAR evidence-based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64(5):669–681. doi:10.1136/ard.2004.028886.15471891
  • Hochberg MC, Altman RD, April KT, et al.; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465–474. doi:10.1002/acr.21596.22563589
  • Migliore A, Bizzi E, Herrero-Beaumont J, Petrella RJ, Raman R, Chevalier X. The discrepancy between recommendations and clinical practice for viscosupplementation in osteoarthritis: mind the gap!. Eur Rev Med Pharmacol Sci. 2015;19(7):1124–1129.25912569
  • Henrotin Y, Raman R, Richette P, et al. Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. Semin Arthritis Rheum. 2015;45(2):140–149. doi:10.1016/j.semarthrit.2015.04.01126094903
  • Paoloni M, Bernetti A, Belelli A, et al. Appropriateness of clinical and organizational criteria for intra-articular injection therapies in osteoarthritis. A Delphi method consensus initiative among experts in Italy. Ann Ist Super Sanita. 2015;51(2):131–138. doi:10.4415/ANN_15_02_1126156184
  • Qvistgaard E, Kristoffersen H, Terslev L, Danneskiold-Samsøe B, Torp-Pedersen S, Bliddal H. Guidance by ultrasound of intra-articular injections in the knee and hip joints. Osteoarthr Cartil. 2001;9:512–517. doi:10.1053/joca.2001.043311520164
  • Migliore A, Martin LS, Alimonti A, Valente C, Tormenta S. Efficacy and safety of viscosupplementation by ultrasound-guided intraarticular injection in osteoarthritis of the hip. Osteoarthr Cartil. 2003;11:305–306. doi:10.1016/S1063-4584(03)00008-612681959
  • Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med. 1997;242(1):27–33. doi:10.1046/j.1365-2796.1997.00170.x9260563
  • Band PA, Heeter J, Wisniewski HG, et al. Hyaluronan molecular weight distribution is associated with the risk of knee osteoarthritis progression. Osteoarthr Cartil. 2015;23(1):70–76. doi:10.1016/j.joca.2014.09.01725266961
  • Balazs EA, Watson D, Duff IF, Roseman S. Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritis human fluids. Arthritis Rheum. 1967;10(4):357–376. doi:10.1002/art.17801004076046018
  • Balazs EA, Denlinger JL. Sodium hyaluronate and joint function. Equine Vet Sci. 1985;5:217–228. doi:10.1016/S0737-0806(85)80102-7
  • Bothner H, Wik O. Rheology of hyaluronate. Acta Otolaryngol Suppl. 1987;442:25–30. doi:10.3109/000164887091028343481162
  • Cullis-Hill D, Ghosh P. The role of hyaluronic acid in joint stability–a hypothesis for hip dysplasia and allied disorders. Med Hypotheses. 1987;23(2):171–185. doi:10.1016/0306-9877(87)90153-83614011
  • Dahl LB, Dahl IM, Engström-Laurent A, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis. 1985;44(12):817–822. doi:10.1136/ard.44.12.8174083937
  • Collins MN, Birkinshaw C. Physical properties of crosslinked hyaluronic acid hydrogels. J Mater Sci Mater Med. 2008;19(11):3335–3343. doi:10.1007/s10856-008-3476-418528637
  • Highley CB, Prestwich GD, Burdick JA. Recent advances in hyaluronic acid hydrogels for biomedical applications. Curr Opin Biotechnol. 2016;40:35–40. doi:10.1016/j.copbio.2016.02.00826930175
  • Finelli I, Chiessi E, Galesso D, Renier D, Paradossi G. Gel-like structure of a hexadecyl derivative of hyaluronic acid for the treatment of osteoarthritis. Macromol Biosci. 2009;9(7):646–653. doi:10.1002/mabi.v9:719384977
  • Finelli I, Chiessi E, Galesso D, Renier D, Paradossi G. A new viscosupplement based on partially hydrophobic hyaluronic acid: a comparative study. Biorheology. 2011;48(5):263–275. doi:10.3233/BIR-2011-059622433568
  • Priano F. Early Efficacy of Intra-Articular HYADD® 4 (Hymovis®) Injections for Symptomatic Knee Osteoarthritis. Joints. 2017;5(2):79–84. doi:10.1055/s-0037-1603677.29114635
  • Bisicchia S, Bernardi G, Tudisco C. HYADD 4 versus methylprednisolone acetate in symptomatic knee osteoarthritis: a single-centre single blind prospective randomised controlled clinical study with 1-year follow-up. Clin Exp Rheumatol. 2016;34(5):857–863.27244700
  • Migliore A, Tormenta S, Massafra U, et al. Repeated ultrasound-guided intra-articular injections of 40 mg of Hyalgan may be useful in symptomatic relief of hip osteoarthritis. Osteoarthr Cartil. 2005;13(12):1126–1127. doi:10.1016/j.joca.2005.08.00116242357
  • Migliore A, Bizzi E, Massafra U, Alimonti A, Martin S, Tormenta S. 18 months follow-up after intra-articular administration of Hyalubrix® in 344 patients with symptomatic osteoarthritis of the hip. Osteoarth Cartil. 2008;16(S4):S118–S119. doi:10.1016/S1063-4584(08)60306-4
  • Migliore A, Tormenta S, Massafra U, et al. Intra-articular administration of hylan G-F 20 in patients with symptomatic hip osteoarthritis: tolerability and effectiveness in a large cohort study in clinical practice. Curr Med Res Opin. 2008;24(5):1309–1316. doi:10.1185/030079908X29193018373891
  • Migliore A, Massafra U, Bizzi E, et al. Comparative, double-blind, controlled study of intra-articular hyaluronic acid (Hyalubrix) injections versus local anesthetic in osteoarthritis of the hip. Arthritis Res Ther. 2009;11(6):R183. doi:10.1186/ar287520003205
  • Migliore A, Massafra U, Bizzi E, et al. Intra-articular injection of hyaluronic acid (MW 1,500–2,000 kDa; HyalOne) in symptomatic osteoarthritis of the hip: a prospective cohort study. Arch Orthop Trauma Surg. 2011;131(12):1677–1685. doi:10.1007/s00402-011-1353-y21814776
  • Migliore A, Massafra U, Frediani B, et al. HyalOne® in the treatment of symptomatic hip OA - data from the ANTIAGE register: seven years of observation. Eur Rev Med Pharmacol Sci. 2017;21(7):1635–1644.28429341
  • Migliore A, Tormenta S, Laganà B, et al. Safety of intra-articular hip injection of hyaluronic acid products by ultrasound guidance: an open study from ANTIAGE register. Eur Rev Med Pharmacol Sci. 2013;17(13):1752–1759.23852899
  • Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494–502. doi:10.1136/ard.16.4.49413498604
  • Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI Guidelines for the Non-Surgical Management of Knee, Hip, and Polyarticular Osteoarthritis. Osteoarthr Cartil. 2019;27(11):S1063-4584(19)31116–1.
  • Rando G, Pastorino R, Chiacchio F, Franzé F. Valutazione degli effetti a lungo termine del trattamento intrarticolare dell’anca con un acido ialuronico reticolare in sportivi affetti da coxartrosi (Long-term effects of intra-articular hip treatment using a reticular hyaluronic acid in sportsmen affected by hip osteoarthritis). Oral communication to the 7th National ANTIAGE Symposium; 10 2018; Rome, Italy.
  • Pavelka K, Niethard FU, Giordan N. A multicentre, international, double blind, randomized, placebo - controlled study to assess the efficacy and safety of 2 different regimens of HYADD4-G in knee osteoarthritis. Osteoarthr Cartil. 2010;18(Supplement 2):S45–S256. doi:10.1016/S1063-4584(10)60353-6
  • Bernetti A, Santilli V. Prospective, Monocentric, Post-CE Mark Study to Assess Efficacy and Safety of Hymovis One (32 Mg/4 Ml) Intra-Articular Injection in Active Patients Affected by Knee Overuse Syndrome. Abstract to the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO). Rome: Abstract Book; 4 2019:342–343. Available from: https://www.wco-iof-esceo.org/sites/wco19/pdf/WCO19-AbstractBook.pdf. Accessed 1019, 2019.
  • Migliore A, Tormenta S, Martin LS, et al. Open pilot study of ultrasound-guided intra-articular injection of hylan G-F 20 (Synvisc) in the treatment of symptomatic hip osteoarthritis. Clin Rheumatol. 2005;24(3):285–289. doi:10.1007/s10067-004-1009-115592903
  • Kocak D, Annaswamy T, Chong S, Arora R. Development of systemic inflammatory polyarthritis after zygapophyseal joint injection with hylan G-F 20 (synvisc-one). Am J Phys Med Rehabil. 2018;97(2):147–149. doi:10.1097/PHM.000000000000079728708631
  • Zhao H, Liu H, Liang X, Li Y, Wang J, Liu C. Hylan G-F 20 versus low molecular weight hyaluronic acids for knee osteoarthritis: a meta-analysis. BioDrugs. 2016;30(5):387–396. doi:10.1007/s40259-016-0186-127435213